Compare · ACHV vs CWBR

ACHV vs CWBR

Side-by-side comparison of Achieve Life Sciences Inc. (ACHV) and CohBar Inc. (CWBR): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both ACHV and CWBR operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
  • ACHV carries a market cap of $697.7M.
  • ACHV has hit the wire 5 times in the past 4 weeks while CWBR has been quiet.
  • ACHV has more recent analyst coverage (11 ratings vs 1 for CWBR).
MetricACHVCWBR
Company
Achieve Life Sciences Inc.
CohBar Inc.
Price
-
-
Market cap
$697.7M
-
1M return
-8.17%
-
1Y return
+57.59%
-
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Exchange
NASDAQ
NASDAQ
IPO
News (4w)
5
0
Recent ratings
11
1
ACHV

Achieve Life Sciences Inc.

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.

CWBR

CohBar Inc.

CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes mellitus, acute respiratory distress syndrome, cancer, atherosclerosis, cardiovascular, and neurodegenerative diseases, such as Alzheimer's disease. Its lead MBT candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial-derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases, CB5064 analogs for COVID-19 associated ARDS, MBT5 analogs for CXCR4-related cancer and orphan diseases, and MBT3 analogs for cancer immunotherapy. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.

Latest ACHV

Latest CWBR